Patients with low and intermediate grade tumours showing high AGR3 expression had an unfavourable outcome (mean tumour-specific survival: 142.5 months ± 9.6; 95% CI: 123.8–161.2) compared to those with low AGR3 expression (mean tumour-specific survival: 181.7 months ± 10.1; 95% CI: 162.0–201.4). This evidence concerns the gene AGR3 and neoplasm.